| Compound Information | SONAR Target prediction |
| Name: | GALANTHAMINE HYDROBROMIDE |
| Unique Identifier: | SPE01501202 |
| MolClass: | Checkout models in ver1.5 and ver1.0 |
| Molecular Formula: | |
| Molecular Weight: | 346.091 g/mol |
| X log p: | 8.526 (online calculus) |
| Lipinksi Failures | 1 |
| TPSA | 21.7 |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptors Count: | 4 |
| Rotatable Bond Count: | 1 |
| Canonical Smiles: | Br.COc1ccc2CN(C)CCC34C=CC(O)CC3Oc1c24 |
| Class: | alkaloid |
| Source: | Galanthus, Narcissus and other Lillaceae |
| Therapeutics: | anticholinesterase, analgesic, antiAlzheimer |
| Generic_name: | Galantamine |
| Chemical_iupac_name: | (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2 ]benzazepin-6-ol |
| Drug_type: | Approved Drug |
| Pharmgkb_id: | PA449726 |
| Kegg_compound_id: | C08526 |
| Drugbank_id: | APRD00206 |
| Melting_point: | 269-270 oC (HBr salt) |
| H2o_solubility: | 10 mg/mL (HBr salt) |
| Logp: | 2.369 |
| Cas_registry_number: | 357-70-0 |
| Mass_spectrum: | http://webbook.nist.gov/cgi/cbook.cgi?Spec=C357700&Index=0&Type=Mass&Large=on |
| Drug_category: | Nootropic Agents; Parasympathomimetics; ATC:N06DA04 |
| Indication: | For the treatment of mild to moderate dementia of the Alzheimer-s type. |
| Pharmacology: | Galantamine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer-s type. Galantamine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, Galantamine-s effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. There is no evidence that Galantamine alters the course of the underlying dementing process. |
| Mechanism_of_action: | Galantamine-s proposed mechanism of action involves the increase of the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. |
| Organisms_affected: | Humans and other mammals |
| Found: 205 nonactive as graph: single | with analogs | 1 2 3 4 5 6 7 8 9 10 Next >> [205] |
| Species: | 4932 |
| Condition: | AAT2 |
| Replicates: | 2 |
| Raw OD Value: r im | 0.7313±0.0000707107 |
| Normalized OD Score: sc h | 0.9890±0.00569058 |
| Z-Score: | -0.5888±0.315419 |
| p-Value: | 0.565722 |
| Z-Factor: | -7.0072 |
| Fitness Defect: | 0.5697 |
| Bioactivity Statement: | Nonactive |
| ps |
| DBLink | Rows returned: 27 | 1 2 3 4 5 Next >> |
| 3449 |
| 9651 |
| 121587 |
| 199254 |
| 199255 |
| 203633 |
| internal high similarity DBLink | Rows returned: 0 |
| active | Cluster 423 | Additional Members: 3 | Rows returned: 0 |
Service provided by the
Mike Tyers Laboratory